Literature DB >> 22523063

Gene therapy: too much splice can spoil the dish.

Didier Trono1.   

Abstract

The use of integrating vectors for gene therapy - required for stable correction of gene expression - carries the risk of insertional mutagenesis, which can lead to activation of a tumorigenic program. In this issue of the JCI, Moiani et al. and Cesana et al. investigate how viral vectors can induce aberrant splicing, resulting in chimeric cellular-viral transcripts. The finding that this is a general phenomenon is concerning, but some of their results do suggest approaches for the development of safeguards in gene therapy vector design.

Mesh:

Substances:

Year:  2012        PMID: 22523063      PMCID: PMC3336998          DOI: 10.1172/JCI63066

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  18 in total

1.  A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency.

Authors:  Salima Hacein-Bey-Abina; Christof von Kalle; Manfred Schmidt; Françoise Le Deist; Nicolas Wulffraat; Elisabeth McIntyre; Isabelle Radford; Jean-Luc Villeval; Christopher C Fraser; Marina Cavazzana-Calvo; Alain Fischer
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

2.  Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts.

Authors:  Arianna Moiani; Ylenia Paleari; Daniela Sartori; Riccardo Mezzadra; Annarita Miccio; Claudia Cattoglio; Fabienne Cocchiarella; Maria Rosa Lidonnici; Giuliana Ferrari; Fulvio Mavilio
Journal:  J Clin Invest       Date:  2012-04-23       Impact factor: 14.808

3.  Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer.

Authors:  Brian D Brown; Mary Anna Venneri; Anna Zingale; Lucia Sergi Sergi; Luigi Naldini
Journal:  Nat Med       Date:  2006-04-23       Impact factor: 53.440

4.  Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state.

Authors:  Brian D Brown; Bernhard Gentner; Alessio Cantore; Silvia Colleoni; Mario Amendola; Anna Zingale; Alessia Baccarini; Giovanna Lazzari; Cesare Galli; Luigi Naldini
Journal:  Nat Biotechnol       Date:  2007-11-16       Impact factor: 54.908

5.  Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.

Authors:  M Cavazzana-Calvo; S Hacein-Bey; G de Saint Basile; F Gross; E Yvon; P Nusbaum; F Selz; C Hue; S Certain; J L Casanova; P Bousso; F L Deist; A Fischer
Journal:  Science       Date:  2000-04-28       Impact factor: 47.728

6.  Whole transcriptome characterization of aberrant splicing events induced by lentiviral vector integrations.

Authors:  Daniela Cesana; Jacopo Sgualdino; Laura Rudilosso; Stefania Merella; Luigi Naldini; Eugenio Montini
Journal:  J Clin Invest       Date:  2012-04-23       Impact factor: 14.808

7.  Gene therapy for immunodeficiency due to adenosine deaminase deficiency.

Authors:  Alessandro Aiuti; Federica Cattaneo; Stefania Galimberti; Ulrike Benninghoff; Barbara Cassani; Luciano Callegaro; Samantha Scaramuzza; Grazia Andolfi; Massimiliano Mirolo; Immacolata Brigida; Antonella Tabucchi; Filippo Carlucci; Martha Eibl; Memet Aker; Shimon Slavin; Hamoud Al-Mousa; Abdulaziz Al Ghonaium; Alina Ferster; Andrea Duppenthaler; Luigi Notarangelo; Uwe Wintergerst; Rebecca H Buckley; Marco Bregni; Sarah Marktel; Maria Grazia Valsecchi; Paolo Rossi; Fabio Ciceri; Roberto Miniero; Claudio Bordignon; Maria-Grazia Roncarolo
Journal:  N Engl J Med       Date:  2009-01-29       Impact factor: 91.245

8.  LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.

Authors:  S Hacein-Bey-Abina; C Von Kalle; M Schmidt; M P McCormack; N Wulffraat; P Leboulch; A Lim; C S Osborne; R Pawliuk; E Morillon; R Sorensen; A Forster; P Fraser; J I Cohen; G de Saint Basile; I Alexander; U Wintergerst; T Frebourg; A Aurias; D Stoppa-Lyonnet; S Romana; I Radford-Weiss; F Gross; F Valensi; E Delabesse; E Macintyre; F Sigaux; J Soulier; L E Leiva; M Wissler; C Prinz; T H Rabbitts; F Le Deist; A Fischer; M Cavazzana-Calvo
Journal:  Science       Date:  2003-10-17       Impact factor: 47.728

9.  Transcription start regions in the human genome are favored targets for MLV integration.

Authors:  Xiaolin Wu; Yuan Li; Bruce Crise; Shawn M Burgess
Journal:  Science       Date:  2003-06-13       Impact factor: 47.728

10.  The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy.

Authors:  Eugenio Montini; Daniela Cesana; Manfred Schmidt; Francesca Sanvito; Cynthia C Bartholomae; Marco Ranzani; Fabrizio Benedicenti; Lucia Sergi Sergi; Alessandro Ambrosi; Maurilio Ponzoni; Claudio Doglioni; Clelia Di Serio; Christof von Kalle; Luigi Naldini
Journal:  J Clin Invest       Date:  2009-03-23       Impact factor: 14.808

View more
  3 in total

1.  In situ bone tissue engineering via ultrasound-mediated gene delivery to endogenous progenitor cells in mini-pigs.

Authors:  Maxim Bez; Dmitriy Sheyn; Wafa Tawackoli; Pablo Avalos; Galina Shapiro; Joseph C Giaconi; Xiaoyu Da; Shiran Ben David; Jayne Gavrity; Hani A Awad; Hyun W Bae; Eric J Ley; Thomas J Kremen; Zulma Gazit; Katherine W Ferrara; Gadi Pelled; Dan Gazit
Journal:  Sci Transl Med       Date:  2017-05-17       Impact factor: 17.956

2.  A single epidermal stem cell strategy for safe ex vivo gene therapy.

Authors:  Stéphanie Droz-Georget Lathion; Ariane Rochat; Graham Knott; Alessandra Recchia; Danielle Martinet; Sara Benmohammed; Nicolas Grasset; Andrea Zaffalon; Nathalie Besuchet Schmutz; Emmanuelle Savioz-Dayer; Jacques Samuel Beckmann; Jacques Rougemont; Fulvio Mavilio; Yann Barrandon
Journal:  EMBO Mol Med       Date:  2015-04       Impact factor: 12.137

3.  Towards a Safer, More Randomized Lentiviral Vector Integration Profile Exploring Artificial LEDGF Chimeras.

Authors:  Lenard S Vranckx; Jonas Demeulemeester; Zeger Debyser; Rik Gijsbers
Journal:  PLoS One       Date:  2016-10-27       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.